Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 257 of 6351
-
New hope for kids with rare cancers: targeted drug repotrectinib enters trial
Disease control Recruiting nowPhase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neur…
Phase 1/2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo shows promise in advanced lung cancer trial
Disease control CompletedThe purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with …
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill combo aims to wipe out breast tumors before surgery
Disease control OngoingThis is a prospective, open label, single-arm study to evaluate the efficacy and safety of neoadjuvant pyrotinib in HER2+ breast cancer patients
Phase 2/3 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug combo shows promise for kids with aggressive brain tumors
Disease control OngoingThis phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells and…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Can a blood thinner prevent strokes in brain bleed survivors?
Disease control Recruiting nowPrimary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with a…
Phase 3 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy aims to stop leukemia from coming back after transplant
Disease control Recruiting nowThis study is being done to see if the addition of a targeted form of radiation to standard conditioning regimen will increase the amount of cancer cells that are killed off in the bone marrow and reduce the chances that your disease may return. This description is called Intensi…
Phase 2 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New 'Sandwich' strategy aims to stop leukemia relapse
Disease control OngoingChimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, relapse after CAR-T has been a major issue. Multi-antigen CAR T and combination with other regimens may reduce the relapse rate. The investig…
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Drug combo aims to shrink Hard-to-Treat sarcomas
Disease control CompletedSoft tissue sarcoma is a relatively rare malignant tumor with an incidence of about 1-2/100,000. The best way to obtain evidence-based medical evidence is to participate in clinical trials with new drugs (especially targeted drugs and immunotherapy). Chidamide, an oral subtype-se…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could a targeted drug shrink advanced cervical tumors?
Disease control CompletedAssess efficacy and safety of cabozantinib in monotherapy in advanced/metastatic cervical cancer (CC) after failure of platinum-based regimen treatment.
Phase 2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can an immunotherapy drug boost the power of chemoradiation against anal cancer?
Disease control OngoingThe RADIANCE multicenter, randomized phase II trial will assess the efficacy of durvalumab, a PD-L1 immune checkpoint inhibitor, in combination with primary mitomycin C (MMC)/5-fluorouracil (5-FU)-based radiochemotherapy (RCT) in patients with locally-advanced anal squamous cell …
Phase 2 • Sponsor: Goethe University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New daily pill aims to tame Crohn's Flare-Ups
Disease control Stopped earlyThis is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the curre…
Phase 2/3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a blood filter calm a kidney disease that drugs Can't?
Disease control Recruiting nowThis multicenter, prospective, single-arm clinical study will evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatme…
Sponsor: Kaneka Medical America LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Heated chemo during surgery may boost ovarian cancer survival
Disease control Ongoingstage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
Phase 3 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Can a Two-Drug combo outsmart resistant colorectal cancer?
Disease control CancelledFruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with immunotherapy and chemotherapy because of its multi-target mechanism which enhances the sen…
Sponsor: Fudan University • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Drug duo targets Hard-to-Treat IDH-Mutated tumors
Disease control OngoingThis is a phase 2 study of the combination of drugs olaparib and durvalumab for the treatment of isocitrate dehydrogenase or (IDH) mutated solid tumors. The purpose of this study is to assess the efficacy of the drug combination via overall response rate and overall disease contr…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could a single infusion of 'Trainer' cells free liver transplant patients from lifelong drugs?
Disease control CompletedPhase I/II, single center, prospective, open-label, non-controlled, non-randomized, interventional, cohort study in which low risk living donor liver transplant (LDLT) recipients who are between 1 and 3 years after transplantation and meet specific criteria (no positive crossmatc…
Phase 1/2 • Sponsor: Angus W. Thomson PhD DSc • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New antibiotic coating could shield heart surgery patients from dangerous infections
Prevention Stopped earlyProspective, Multinational, Multicenter, Randomized, Parallel Controlled, Two arms, Single Blind, Study to Assess the Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SOC) IV Prophylactic Antibiotic Treatment vs. SOC in Prevention of Post-Cardia…
Phase 3 • Sponsor: PolyPid Ltd. • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
New pill could cut recurrence risk in aggressive breast cancer
Disease control Recruiting nowThis is a prospective, randomised, multicenter, no placebo-controlled, open label study for evaluating the efficacy and safety of pyrotinib in women with residual invasive HER2-positive breast cancer after neoadjuvant chemotherapy plus anti-HER2 target therapy. The main purpose i…
Phase 3 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:06 UTC
-
Surgery or pills? new study tests best way to treat teen diabetes
Disease control OngoingThis study will test the hypothesis that metabolic bariatric surgery will be more effective at providing durable glycemic control and reduce co-morbidities than intensive medical therapy in youth with type 2 diabetes.
Phase 4 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New shot could tame uncontrollable itch of prurigo nodularis
Disease control CompletedPrimary Objective: To demonstrate the efficacy of dupilumab on itch response in participants with prurigo nodularis (PN), inadequately controlled on topical prescription therapies or when those therapies are not advisable. Secondary Objectives: To demonstrate the efficacy of d…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 18:24 UTC